SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced ...
Title: Efficacy and Safety of Olutasidenib Monotherapy in Primary Refractory AML: A Post Hoc Analysis of a Phase 2 Study Presenter: Antonio Curti, M.D., Ph.D. In the pivotal cohort of R/R AML patients ...
SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two ...
SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will ...
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Initial data from the dose escalation phase using a July 15, 2024 data cutoff date indicate that ...
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS Rigel's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback